TY - JOUR
T1 - A New Regimen of Interleukin 2 and Lymphokine-Activated Killer Cells
T2 - Efficacy Without Significant Toxicity
AU - Eberlein, Timothy J.
AU - Schoof, Deric D.
AU - Jung, Sung Eun
AU - Davidson, David
AU - Gramolini, Barbara
AU - Mcgrath, Kathleen
AU - Massaro, Anthony
AU - Wilson, Richard E.
PY - 1988/12
Y1 - 1988/12
N2 - Adoptive immunotherapy with high-dose interleukin 2 and lymphokine-activated killer (LAK) cells has proved to be successful in the treatment of some patients with metastatic cancer, but not without a significant degree of associated toxic effects. The primary goal of this study was to substantially reduce the toxicity of this complex and expensive treatment, while maintaining or improving efficacy. To this end, 29 patients were treated with LAK cells in conjunction with a low-dose regimen of interleukin 2 and a prolonged period of administration following LAK cell infusion. This protocol resulted in a considerable reduction in toxicity, as compared with that described in previous studies, without compromising the efficacy. This study offers further confirmation that adoptive immunotherapy of metastatic cancer can be clinically beneficial to patients for whom no other effective therapy is presently available.
AB - Adoptive immunotherapy with high-dose interleukin 2 and lymphokine-activated killer (LAK) cells has proved to be successful in the treatment of some patients with metastatic cancer, but not without a significant degree of associated toxic effects. The primary goal of this study was to substantially reduce the toxicity of this complex and expensive treatment, while maintaining or improving efficacy. To this end, 29 patients were treated with LAK cells in conjunction with a low-dose regimen of interleukin 2 and a prolonged period of administration following LAK cell infusion. This protocol resulted in a considerable reduction in toxicity, as compared with that described in previous studies, without compromising the efficacy. This study offers further confirmation that adoptive immunotherapy of metastatic cancer can be clinically beneficial to patients for whom no other effective therapy is presently available.
UR - http://www.scopus.com/inward/record.url?scp=0024226986&partnerID=8YFLogxK
U2 - 10.1001/archinte.1988.00380120039008
DO - 10.1001/archinte.1988.00380120039008
M3 - Article
C2 - 3264142
AN - SCOPUS:0024226986
SN - 0003-9926
VL - 148
SP - 2571
EP - 2576
JO - Archives of internal medicine
JF - Archives of internal medicine
IS - 12
ER -